Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.

BACKGROUND AND OBJECTIVES We assessed whether nonalcoholic steatohepatitis (NASH) diagnosed by liver biopsy is associated with decreased kidney function and whether such association is independent of insulin resistance and features of the metabolic syndrome. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS We enrolled 80 consecutive overweight patients with biopsy-proven NASH and 80 nonsteatotic control subjects who were matched for age, gender, and body mass index. Chronic kidney disease (CKD) was defined as the presence of estimated GFR (eGFR) of ≤60 ml/min per 1.73 m(2) and/or abnormal albuminuria (i.e., urinary albumin/creatinine ratio ≥30 mg/g). RESULTS NASH patients had significantly (P < 0.001) lower eGFR (75.3 ± 12 versus 87.5 ± 6 ml/min per 1.73 m(2)) and a greater frequency of abnormal albuminuria (14 versus 2.5%) and CKD (25 versus 3.7%) than control subjects. The significant differences in eGFR, albuminuria, and CKD that were observed between the two groups were only slightly weakened after adjustment for age, gender, body mass index, smoking status, insulin resistance (by homeostasis model assessment), and components of the metabolic syndrome. Notably, histologic severity of NASH (i.e., fibrosis stage) was strongly associated with either decreasing eGFR or increasing albuminuria (P < 0.01 or less), independently of potential confounding factors. CONCLUSIONS Our findings suggest that patients with biopsy-proven NASH have moderately decreased eGFR and a higher frequency of abnormal albuminuria and CKD than matched control subjects and that the severity of NASH histology is associated with decreased kidney function, independently of traditional risk factors, insulin resistance, and components of the metabolic syndrome.

[1]  G. Lippi,et al.  Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001–2006 , 2009, Clinical chemistry and laboratory medicine.

[2]  H. Tilg,et al.  Insulin resistance, inflammation, and non-alcoholic fatty liver disease , 2008, Trends in Endocrinology & Metabolism.

[3]  P. Fesler,et al.  Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  M. Chonchol,et al.  Relationship between serum gamma-glutamyltransferase concentrations and chronic kidney disease in the United States population. Findings from the National Health and Nutrition Examination Survey 2001-2006. , 2010 .

[5]  Tom Greene,et al.  Assessing kidney function--measured and estimated glomerular filtration rate. , 2006, The New England journal of medicine.

[6]  G. Marchesini,et al.  Obesity-associated liver disease. , 2008, The Journal of clinical endocrinology and metabolism.

[7]  Hirokazu Takahashi,et al.  High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH , 2007, Journal of Gastroenterology.

[8]  S. Bagby Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? , 2004, Journal of the American Society of Nephrology : JASN.

[9]  G. Marchesini,et al.  Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? , 2008, Diabetologia.

[10]  Raj Vuppalanchi,et al.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management , 2009, Hepatology.

[11]  C. Day,et al.  Non-alcoholic fatty liver disease: the mist gradually clears. , 2008, Journal of hepatology.

[12]  M. Chonchol,et al.  Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. , 2009, Seminars in thrombosis and hemostasis.

[13]  S. Bischoff,et al.  Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. , 2008, The Journal of nutrition.

[14]  V. Wong,et al.  Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients , 2006, Diabetologia.

[15]  M. Sarnak,et al.  Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. , 2005, The Medical clinics of North America.

[16]  Won-Young Lee,et al.  Impact of non‐alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes , 2010, Internal medicine journal.

[17]  G. Lippi,et al.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients , 2010, Diabetologia.

[18]  Yoosoo Chang,et al.  Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. , 2008, Metabolism: clinical and experimental.

[19]  M. Chonchol,et al.  Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease , 2008, Nature Clinical Practice Nephrology.

[20]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[21]  Y. Yılmaz,et al.  Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. , 2010, Metabolism: clinical and experimental.

[22]  G. Lippi,et al.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients , 2008, Diabetologia.

[23]  Manisha Talim,et al.  Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients , 2007, Diabetes Care.

[24]  G. Chertow,et al.  Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. , 2005, Journal of the American Society of Nephrology : JASN.

[25]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[26]  M. Chonchol,et al.  Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[27]  Daniel Levy,et al.  Predictors of new-onset kidney disease in a community-based population. , 2004, JAMA.

[28]  Yoosoo Chang,et al.  gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. , 2007, Clinical chemistry.

[29]  A. Feldstein,et al.  Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis , 2008, The American Journal of Gastroenterology.

[30]  D. Jacobs,et al.  Serum γ-Glutamyltransferase Was Differently Associated with Microalbuminuria by Status of Hypertension or Diabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) Study , 2005 .

[31]  E. Bonora,et al.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.

[32]  G. Lippi,et al.  Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. , 2008, Journal of the American Society of Nephrology : JASN.

[33]  G. Lippi,et al.  NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men , 2008, Obesity.

[34]  R. Mak,et al.  Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.